Navigation Links
Barr Reports Second Quarter 2008 GAAP Earnings of $0.52 Per Share; Adjusted Earnings of $0.64 Per Share
Date:8/7/2008

1,105 923

Total assets 4,970 4,762

Total debt 2,004 2,080

Shareholders' equity 2,158 1,866

Reconciliation of Adjusted Earnings to GAAP Earnings; EBITDA

To supplement its consolidated financial statements presented in accordance with accounting principles generally accepted in the United States of America ("GAAP"), the Company is providing the supplemental financial information contained below to reflect (1) the adjusted earnings per share effect of certain unusual or infrequent charges or benefits that were taken or received in the quarter ended June 30, 2008, and (2) the calculation of EBITDA for each period presented.

Adjusted earnings per share and EBITDA are non-GAAP financial measures. The Company is providing this information, however, because it believes that such information is useful to both management and investors in that it facilitates analysis by both management and investors in evaluating the Company's performance and trends. The presentation of this additional information is not meant to be considered in isolation of, or as a substitute for, results prepared in accordance with GAAP.

Barr Pharmaceuticals, Inc. Selected Adjusted Financial Data

(in millions, except per share data)

Three Months Ended June 30, 2008

Adjusted

GAAP Adjustments Earnings

Revenues:

Product sales $675 - $675

Alliance and development revenue 93 (53)(f) 40

Other revenue 11 (6)(b) 5

Total revenues 779 (59) 720

Costs and expenses:

Cost of sales 353 (65)(b),(c),(d) 288

Selli
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
2. Caliper Life Sciences Reports Second Quarter 2008 Results
3. Watson Pharmaceuticals Reports Second Quarter 2008 Results
4. EntreMed Reports Second Quarter 2008 Financial Results
5. Transgenomic Reports Second Quarter 2008 Results
6. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
7. Bionovo Reports Second Quarter 2008 Financial Results
8. AtriCure Reports Record Second Quarter 2008 Financial Results
9. AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008
10. eResearchTechnology Reports Second Quarter 2008 Results
11. SuperGen Reports 2008 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... NEW YORK , September 2, 2014 ... Market Study on Membrane Technology in Pharmaceutical, Biopharma and ... Witness Highest Growth by 2019" the global membrane technology market for ... 7,029.9 million in 2014 and is expected to grow ... to reach an estimated value of USD 10,886.0 million ...
(Date:9/2/2014)... Opertech Bio, Inc., a company that ... approach to sensory evaluation, today announced the issuance ... Patent and Trademark Office, encompassing high-throughput sensory discrimination ... taste evaluation technology called Microtiter Operant Gustometer or ... for rapid characterization of taste sensory properties,” said ...
(Date:9/2/2014)... 2014  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... candidates targeting specific pathogens that cause serious infections ... final preclinical toxicology study of SYN-004. Per U.S. ... study was required to move the Company,s lead ... devastating effects of Clostridium difficile (C. difficile), ...
(Date:9/2/2014)... September 2, 2014 Culot brings ... and lab management services  BioData, producer of ... pleased to announce the appointment of Louis Culot ... served as VP Marketing and Business Development at BioDiscovery ... and clinical applications. Previously, Culot worked for ...
Breaking Biology Technology:Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 3Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 4Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 5Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5Louis Culot Appointed as BioData's CEO 2
... 29 Abt Associates has been,ranked 19th in the ... 50 U.S. Research firms. The listing is based on ... research revenue for,calendar 2007 was $55.1 million. Total company ... $225 million., Abt Associates market research activities are ...
... Purification Testing, Standards and Procedures, SHAANXI, China, ... (OTC Bulletin Board: HFGB), a leading,developer and producer ... the,production of pharmaceuticals, nutraceuticals and food production, today,released ... application for COS,approval for the delivery of Diosmin ...
... Volcano Corporation,(Nasdaq: VOLC ), a leading ... (FM) and Optical Coherence,Tomography (OCT) products designed to ... vascular disease, today announced that it will,report its ... six months of,fiscal 2008 on Tuesday, August 5., ...
Cached Biology Technology:Abt Associates Ranked One of Top 20 U.S. Market Research Firms 2Huifeng Bio-Pharmaceutical (HFGB) Provides Update on COS Application Status 2Huifeng Bio-Pharmaceutical (HFGB) Provides Update on COS Application Status 3Volcano Corporation Schedules Second Quarter Conference Call, Webcast 2
(Date:9/2/2014)... the battle between our immune systems and cholera bacteria, ... known as phages. In a new study, researchers from ... National Public Health Laboratory, and elsewhere, report that phages ... in order to survive. Importantly, the study published ... escape from phage predation occurs during human infection. , ...
(Date:9/2/2014)... Kean stops by Reactions this week to debunk the ... despite what "Shark Week" may lead you to believe, ... http://youtu.be/KhFygIoW_MA . , Kean,s book, "The Disappearing Spoon: And ... of the World from the Periodic Table of the ... video series produced for the newly launched American Association ...
(Date:9/2/2014)... touch a hot oven, you rapidly pull your hand ... in sensing and responding to such painful stimuli, they ... researchers have made a surprising discovery about the role ... and have built a structural model of the molecule. ... , may help direct new strategies to treat pain ...
Breaking Biology News(10 mins):War between bacteria and phages benefits humans 2War between bacteria and phages benefits humans 3Surprising new role for calcium in sensing pain 2Surprising new role for calcium in sensing pain 3
... University of the Negev researcher Dr. Taleb Mokari, a ... and Technology, has been awarded a prestigious Krill Prize ... the Prize for his work on developing novel nanostructures ... a senior lecturer in BGU,s Department of Chemistry. His ...
... of time families spend eating meals together has been ... teens, with families who eat together regularly reporting declines ... their children. Now, a new study that looks at ... family interactions during mealtime affected the children,s health. ...
... percent of dairy herds and causes an estimated annual ... A contagious, chronic and usually fatal bacterial infection of ... milk production, causes weight loss in cows, and contributes ... Institute for Mathematical and Biological Synthesis (NIMBioS) is now ...
Cached Biology News:Family mealtimes play a role in health of children with asthma 2Wasting disease in cattle focus of workshop 2
EGTA, 10 g. Ethylene glycol-O,O-bis-[2-amino-ethyl]-N,N,N,N,-tetraacetic acid.Assay: > 99.0%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
...
RABBIT ANTI D-TYROSINE CONJUGATE...
... PCR Spots, Oligo Spots and complementary RNA ... microarray experiments. Use for glass array printing ... for reverse transcription, cDNA labeling, hybridization stringency ... Control PCR Spots and Oligo Spots, ...
Biology Products: